Aspirin, Ibuprofen, and the Risk of Colorectal Cancer in Lynch Syndrome.

BACKGROUND Inheritance of a germline mutation in one of the DNA mismatch repair (MMR) genes MLH1, MSH2, MSH6, and PMS2 causes a high risk of colorectal and other cancers (Lynch Syndrome). Use of aspirin has been shown to be associated with a reduced risk of colorectal cancer for the general population as well as for MMR gene mutation carriers. The aim of this study was to determine whether use of aspirin and ibuprofen in a nontrial setting is associated with the risk of colorectal cancer risk for MMR gene mutation carriers. METHODS We included 1858 participants in the Colon Cancer Family Registry who had been found to have a pathogenic germline mutation in a MMR gene (carriers). We used weighted Cox proportional hazards regression to estimate hazard ratios (HRs) and 95% confidence intervals (CIs). All statistical tests were two-sided. RESULTS A total of 714 carriers (38%) were diagnosed with colorectal cancer at a mean age of 42.4 (standard deviation 10.6) years. A reduced risk of colorectal cancer was associated with aspirin use (for 1 month to 4.9 years: HR = 0.49, 95% CI = 0.27 to 0.90, P = .02; for ≥5 years: HR = 0.25, 95% CI = 0.10 to 0.62, P = .003) and ibuprofen use (for 1 month to 4.9 years: HR = 0.38, 95% CI = 0.18 to 0.79, P = .009; for ≥5 years: HR = 0.26, 95% CI = 0.10 to 0.69, P = .007), compared with less than one month of use. CONCLUSION Our results provide additional evidence that, for MMR gene mutation carriers, use of aspirin and ibuprofen might be effective in reducing their high risk of colorectal cancer.

[1]  N. Cook,et al.  Individualised prediction of alternate-day aspirin treatment effects on the combined risk of cancer, cardiovascular disease and gastrointestinal bleeding in healthy women , 2014, Heart.

[2]  Y. Hirooka,et al.  Risk factors of symptomatic NSAID‐induced small intestinal injury and diaphragm disease , 2014, Alimentary pharmacology & therapeutics.

[3]  N. Cook,et al.  Estimates of benefits and harms of prophylactic use of aspirin in the general population , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  S. Kudo,et al.  The preventive effects of low-dose enteric-coated aspirin tablets on the development of colorectal tumours in Asian patients: a randomised trial , 2014, Gut.

[5]  X. Ye,et al.  Dose–Risk and Duration–Risk Relationships between Aspirin and Colorectal Cancer: A Meta-Analysis of Published Cohort Studies , 2013, PloS one.

[6]  P. Møller,et al.  Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts , 2013, Gut.

[7]  D. Bishop,et al.  Edinburgh Research Explorer Long-term effect of resistant starch on cancer risk in carriers of hereditary colorectal cancer , 2022 .

[8]  P. Moayyedi,et al.  Does aspirin really reduce the risk of colon cancer? , 2012, The Lancet.

[9]  Aung Ko Win,et al.  Substantial unexplained variation in cancer risks for MLH1 and MSH2 mutation carriers , 2012, Human mutation.

[10]  Aung Ko Win,et al.  Colorectal and other cancer risks for carriers and noncarriers from families with a DNA mismatch repair gene mutation: a prospective cohort study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Rodney J Scott,et al.  Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial , 2011, The Lancet.

[12]  F. Couch,et al.  Modification of BRCA1-Associated Breast and Ovarian Cancer Risk by BRCA1-Interacting Genes. , 2011, Cancer research.

[13]  D. Bishop,et al.  A Randomized Placebo-Controlled Prevention Trial of Aspirin and/or Resistant Starch in Young People with Familial Adenomatous Polyposis , 2011, Cancer Prevention Research.

[14]  Aung Ko Win,et al.  Body Mass Index in Early Adulthood and Endometrial Cancer Risk for Mismatch Repair Gene Mutation Carriers , 2011, Obstetrics and gynecology.

[15]  Emily J. Greenspan,et al.  Ibuprofen Inhibits Activation of Nuclear β-Catenin in Human Colon Adenomas and Induces the Phosphorylation of GSK-3β , 2011, Cancer Prevention Research.

[16]  A. de la Chapelle,et al.  The Search for Unaffected Individuals with Lynch Syndrome: Do the Ends Justify the Means? , 2011, Cancer Prevention Research.

[17]  A. Algra,et al.  Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials , 2010, The Lancet.

[18]  Brendan Delaney,et al.  Diagnosis and management of Barrett’s oesophagus , 2010, BMJ : British Medical Journal.

[19]  R. Steele,et al.  Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002) , 2010, Gut.

[20]  Samy Suissa,et al.  Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes , 2010, BMJ : British Medical Journal.

[21]  J. Potter,et al.  Smoking and Colorectal Cancer in Lynch Syndrome: Results from the Colon Cancer Family Registry and The University of Texas M.D. Anderson Cancer Center , 2010, Clinical Cancer Research.

[22]  H T Lynch,et al.  Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications , 2009, Clinical genetics.

[23]  M. Thun,et al.  Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. , 2009, The Lancet. Oncology.

[24]  J. Baron,et al.  Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. , 2009, Journal of the National Cancer Institute.

[25]  J. Potter,et al.  The clinical phenotype of Lynch syndrome due to germ-line PMS2 mutations. , 2008, Gastroenterology.

[26]  P. Maisonneuve,et al.  Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps. , 2008, Gastroenterology.

[27]  B. Levin,et al.  Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. , 2008, Gastroenterology.

[28]  Dieter Niederacher,et al.  Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. , 2008, American journal of human genetics.

[29]  David W. Hosmer,et al.  Applied Survival Analysis: Regression Modeling of Time-to-Event Data , 2008 .

[30]  Samy Suissa,et al.  Immortal time bias in pharmaco-epidemiology. , 2008, American journal of epidemiology.

[31]  John D Potter,et al.  Colon Cancer Family Registry: An International Resource for Studies of the Genetic Epidemiology of Colon Cancer , 2007, Cancer Epidemiology Biomarkers & Prevention.

[32]  Shuji Ogino,et al.  Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. , 2007, The New England journal of medicine.

[33]  P. Rothwell,et al.  Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies , 2007, The Lancet.

[34]  G. Petersen,et al.  Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review. , 2006, JAMA.

[35]  J. Chang-Claude,et al.  Effect of chest X-rays on the risk of breast cancer among BRCA1/2 mutation carriers in the international BRCA1/2 carrier cohort study: a report from the EMBRACE, GENEPSO, GEO-HEBON, and IBCCS Collaborators' Group. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  G. Giles,et al.  Cancer risks for mismatch repair gene mutation carriers: a population-based early onset case-family study. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[37]  John L Hopper,et al.  Use of molecular tumor characteristics to prioritize mismatch repair gene testing in early-onset colorectal cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  J. Chang-Claude,et al.  A weighted cohort approach for analysing factors modifying disease risks in carriers of high‐risk susceptibility genes , 2005, Genetic epidemiology.

[39]  Z. Halpern,et al.  Rofecoxib Reduces Polyp Recurrence in Familial Polyposis , 2003, Digestive Diseases and Sciences.

[40]  Douglas G Altman,et al.  Interaction revisited: the difference between two estimates , 2003, BMJ : British Medical Journal.

[41]  Michael J Thun,et al.  Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. , 2002, Journal of the National Cancer Institute.

[42]  W. Zoller,et al.  [Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer]. , 2001, Zeitschrift fur Gastroenterologie.

[43]  J. Marx Anti-Inflammatories Inhibit Cancer Growth--But How? , 2001, Science.

[44]  L. Aaltonen,et al.  Population carrier frequency of hMSH2 and hMLH1 mutations , 2000, British Journal of Cancer.

[45]  B. Levin,et al.  The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. , 2000, The New England journal of medicine.

[46]  R L Williams,et al.  A Note on Robust Variance Estimation for Cluster‐Correlated Data , 2000, Biometrics.

[47]  S. Shapiro,et al.  The risk of acute major upper gastrointestinal bleeding among users of aspirin and ibuprofen at various levels of alcohol consumption , 1999, American Journal of Gastroenterology.

[48]  K. Kinzler,et al.  PPARδ Is an APC-Regulated Target of Nonsteroidal Anti-Inflammatory Drugs , 1999, Cell.

[49]  K. Kinzler,et al.  Mechanisms underlying nonsteroidal antiinflammatory drug-mediated apoptosis. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[50]  P. Remington,et al.  Nonsteroidal anti-inflammatory drug use and protection against colorectal cancer in women. , 1996, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[51]  R. DuBois,et al.  Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2 , 1995, Cell.

[52]  K. Schmid,et al.  Complete reversion and prevention of rectal adenomas in colectomized patients with familial adenomatous polyposis by rectal low-dose sulindac maintenance treatment , 1995, Diseases of the colon and rectum.

[53]  P. Grambsch,et al.  Proportional hazards tests and diagnostics based on weighted residuals , 1994 .

[54]  S. Piantadosi,et al.  Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. , 1993, The New England journal of medicine.

[55]  L F Watson,et al.  Colorectal cancer risk, chronic illnesses, operations and medications: case control results from the Melbourne Colorectal Cancer Study. 1988. , 2007, International journal of epidemiology.

[56]  A. Price,et al.  Clinicopathological features of nonsteroidal antiinflammatory drug-induced small intestinal strictures. , 1988, Gastroenterology.

[57]  P. Laird,et al.  Frequency of deletions of EPCAM (TACSTD1) in MSH2-associated Lynch syndrome cases. , 2011, The Journal of molecular diagnostics : JMD.

[58]  F. Couch,et al.  Modification of BRCA 1-Associated Breast and Ovarian Cancer Risk by BRCA 1-Interacting Genes , 2011 .

[59]  Feng Yang,et al.  Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome. , 2009, The New England journal of medicine.

[60]  J. Meyerhardt,et al.  Aspirin dose and duration of use and risk of colorectal cancer in men. , 2008, Gastroenterology.

[61]  J. Hopper Application of genetics to the prevention of colorectal cancer. , 2005, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[62]  J. Marx Cancer research. Anti-inflammatories inhibit cancer growth--but how? , 2001, Science.

[63]  K. Kinzler,et al.  PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs. , 1999, Cell.

[64]  L. Aaltonen,et al.  A novel approach to estimate the proportion of hereditary nonpolyposis colorectal cancer of total colorectal cancer burden. , 1994, Cancer detection and prevention.

[65]  W. Rogers Regression standard errors in clustered samples , 1994 .

[66]  T. Westfall,et al.  ALTERATIONS IN THE , 1985 .